Polaryx Therapeutics, Inc. PLYX 深 滬
已收盤 08-07 16:00:00 美东时间
2.26
+0.040
+1.80%
華盛通- 最 高2.30
- 今 開2.18
- 成交量 6.99万股
- 最 低 2.18
- 昨 收 2.22
- 總市值 1.13亿
- 52周最高 48.91
- 市盈率 靜 --
- 換手率 0.14%
- 52周最低 1.86
- 委 比 -12.66%
- 總股本 4984.60万
- 歷史最高 48.91
- 量 比 0.79
- 振 幅 5.41%
- 歷史最低 1.86
- 每 手 1
- 風險率 5.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
LUCID CAPITAL MARKETS Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
07-27 20:04
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
HC Wainwright & Co. Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $7.
07-09 18:09
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 33.0% to $2.5 during F...
05-30 05:05
Polaryx Therapeutics shares are trading higher after the company announced closing of a $10 million private investment in public equity financing.
Polaryx Therapeutics shares are trading higher after the company announced clos...
05-28 23:24
Why Polaryx Therapeutics Stock Is Surging On Thursday?
Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA trial for rare lysosomal storage disorders.
05-28 22:45
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers BioLine Rx (NASDAQ:BLRX) stock increased by 12.5% to $3.11 during Mond...
05-19 05:05
Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of JNCL/CLN3 Disease, Krabbe Disease, And Sandhoff Disease
Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has
04-21 20:37
Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis
Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc.
03-17 20:33
